JP2021102644A5 - - Google Patents

Download PDF

Info

Publication number
JP2021102644A5
JP2021102644A5 JP2021054632A JP2021054632A JP2021102644A5 JP 2021102644 A5 JP2021102644 A5 JP 2021102644A5 JP 2021054632 A JP2021054632 A JP 2021054632A JP 2021054632 A JP2021054632 A JP 2021054632A JP 2021102644 A5 JP2021102644 A5 JP 2021102644A5
Authority
JP
Japan
Prior art keywords
amount
pharmaceutical composition
serum
per unit
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021054632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021102644A (ja
Filing date
Publication date
Priority claimed from JP2019172758A external-priority patent/JP2020063237A/ja
Application filed filed Critical
Publication of JP2021102644A publication Critical patent/JP2021102644A/ja
Publication of JP2021102644A5 publication Critical patent/JP2021102644A5/ja
Priority to JP2022175999A priority Critical patent/JP2023011815A/ja
Pending legal-status Critical Current

Links

JP2021054632A 2013-03-15 2021-03-29 抗ｉｌ−２３抗体を用いた乾癬の治療方法 Pending JP2021102644A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022175999A JP2023011815A (ja) 2013-03-15 2022-11-02 抗ｉｌ－２３抗体を用いた乾癬の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15
US61/789,777 2013-03-15
JP2019172758A JP2020063237A (ja) 2013-03-15 2019-09-24 抗ｉｌ−２３抗体を用いた乾癬の治療方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019172758A Division JP2020063237A (ja) 2013-03-15 2019-09-24 抗ｉｌ−２３抗体を用いた乾癬の治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022175999A Division JP2023011815A (ja) 2013-03-15 2022-11-02 抗ｉｌ－２３抗体を用いた乾癬の治療方法

Publications (2)

Publication Number Publication Date
JP2021102644A JP2021102644A (ja) 2021-07-15
JP2021102644A5 true JP2021102644A5 (https=) 2021-09-02

Family

ID=50336511

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016500381A Pending JP2016517408A (ja) 2013-03-15 2014-02-25 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2019172758A Pending JP2020063237A (ja) 2013-03-15 2019-09-24 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2021054632A Pending JP2021102644A (ja) 2013-03-15 2021-03-29 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2022175999A Withdrawn JP2023011815A (ja) 2013-03-15 2022-11-02 抗ｉｌ－２３抗体を用いた乾癬の治療方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016500381A Pending JP2016517408A (ja) 2013-03-15 2014-02-25 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2019172758A Pending JP2020063237A (ja) 2013-03-15 2019-09-24 抗ｉｌ−２３抗体を用いた乾癬の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022175999A Withdrawn JP2023011815A (ja) 2013-03-15 2022-11-02 抗ｉｌ－２３抗体を用いた乾癬の治療方法

Country Status (17)

Country Link
US (3) US20160060337A1 (https=)
EP (2) EP2968488A1 (https=)
JP (4) JP2016517408A (https=)
KR (1) KR20150128858A (https=)
CN (1) CN105209064A (https=)
AP (1) AP2015008803A0 (https=)
AU (3) AU2014238148A1 (https=)
CA (1) CA2906382A1 (https=)
CL (1) CL2015002723A1 (https=)
CR (1) CR20150572A (https=)
EA (1) EA201591581A1 (https=)
HK (1) HK1219425A1 (https=)
IL (2) IL241342A0 (https=)
PH (2) PH12015502129A1 (https=)
SG (2) SG11201507482UA (https=)
TN (1) TN2015000403A1 (https=)
WO (1) WO2014149425A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
CN107206081A (zh) * 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
AU2017241776B2 (en) * 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
EP3560956A3 (en) * 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
WO2020016838A2 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
MX2021005236A (es) * 2018-11-05 2021-06-18 Merck Sharp & Dohme Llc Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
MX2021011328A (es) * 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
EP1977007A4 (en) * 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
EP2426145B1 (en) * 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
WO2010002776A2 (en) 2008-06-30 2010-01-07 Black & Decker Inc. Cord protector for power tools
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
EP2596022A4 (en) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
PH12013500660B1 (en) * 2010-10-08 2017-10-27 Novartis Ag Methods of treating psoriasis using il-17 antagonists
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23

Similar Documents

Publication Publication Date Title
JP2021102644A5 (https=)
JP5129122B2 (ja) 癌治療のための抗体およびグルココルチコイドの組み合わせ
AU2014337385B2 (en) Chimeric antigen receptor T cell switches and uses thereof
US20220000872A1 (en) Method of enhancing immune-based therapy
JP2014114288A5 (https=)
JP2006527193A5 (https=)
JP2016509009A (ja) Ｔ制御性細胞の増殖または枯渇方法
JP2013543501A5 (https=)
JP2011513492A (ja) 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
TW202106334A (zh) 藉由投予ｉｌ－３３拮抗劑治療或預防哮喘之方法
CN103038256A (zh) 用抗cd3免疫分子疗法治疗肝炎的方法及组合物
Pitarokoili et al. Induction of regulatory properties in the intestinal immune system by dimethyl fumarate in Lewis rat experimental autoimmune neuritis
JP2016510766A (ja) １型糖尿病の処置及び／又は予防のための方法及び組成物
JP2006514681A5 (https=)
WO2016119308A1 (zh) 一种抗肿瘤制剂及其制备方法
FR2769505A1 (fr) Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
CN110859959A (zh) 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途
TW202034925A (zh) Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
CN119546337A (zh) 通过施用il-4r拮抗剂治疗小儿嗜酸性粒细胞性食管炎的方法
EP4458413A2 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
JPWO2021092056A5 (https=)
Stephen et al. A comparative study of once daily versus twice daily tacrolimus in liver transplantation
WO2008061429A1 (fr) Procédé d'utilisation de triacontanol visant à préparer des médicaments destinés à traiter des cancers
AU2021104207A4 (en) Halloysite nanotube as a modified drug release carrier for 6-mercaptopurine